

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.		FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
	10/081,393	02	2/20/2002	Larry E. Morrison	01886-071001/ V0079	1580	
	26161	7590	11/07/2003		EXAM	INER	
	FISH & RICHARDSON PC 225 FRANKLIN ST			CHAKRABAF	RTI, ARUN K		
	BOSTON, MA 02110				ART UNIT	PAPER NUMBER	
	•				1634		

DATE MAILED: 11/07/2003

 $\partial_x^{\rm st}$

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 10/081,393 Applicant(s)

Morrison

Examiner

Arun Chakrabarti

Art Unit 1634



	The MAILING DATE of this communication appears	on the cover sheet w	vith the correspondence address	
Period fo	or Reply			
THE N	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION. ons of time may be available under the provisions of 37 CFR 1.136 (a). In	-		
- If the pe - If NO pe - Feilure t - Any rep	date of this communication. eriod for reply specified above is less than thirty (30) days, a reply within the eriod for reply is specified above, the maximum statutory period will apply a to reply within the set or extended period for reply will, by statute, cause the payer of the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	and will expire SIX (6) MONT he application to become ABA	THS from the mailing date of this communication, BANDONED (35 U.S.C. § 133),	
Status				
1) 💢	Responsive to communication(s) filed on Oct 8, 20	03		
2a) 🗌	This action is FINAL . 2b) ☒ This act	ion is non-final.		
	Since this application is in condition for allowance ϵ closed in accordance with the practice under ϵx pair	•		
	ion of Claims			
4) 💢	Claim(s) <u>1-20</u>		is/are pending in the application.	
48	a) Of the above, claim(s) <u>8-20</u>		is/are withdrawn from consideration.	
5) 🗆	Claim(s)		is/are allowed.	
6) 💢	Claim(s) 1-7		is/are rejected.	
	Claim(s)			
	Claims			
	tion Papers			
9) 🗆	The specification is objected to by the Examiner.			
10)	The drawing(s) filed on is/are	a) accepted or	b)□ objected to by the Examiner.	
	Applicant may not request that any objection to the d	rawing(s) be held in	abeyance. See 37 CFR 1.85(a).	
11)	The proposed drawing correction filed on	is: a) 🗆	\exists approved b) \Box disapproved by the Examine	r.
	If approved, corrected drawings are required in reply t	to this Office action.		İ
12)	The oath or declaration is objected to by the Exami	ner.		
Priority (under 35 U.S.C. §§ 119 and 120			
13)	Acknowledgement is made of a claim for foreign pr	iority under 35 U.S	3.C. § 119(a)-(d) or (f).	
a) 🗆	All b)□ Some* c)□ None of:			
1	. \square Certified copies of the priority documents have	e been received.		ļ
2	2. \square Certified copies of the priority documents have	e been received in /	Application No	ļ
	3. Copies of the certified copies of the priority do application from the International Bures	au (PCT Rule 17.2(a	a)).	
_	the the attached detailed Office action for a list of the			
. 🗂	Acknowledgement is made of a claim for domestic			
a) ⊔ 15) □				
Attachme	Acknowledgement is made of a claim for domestic	priority uniter 35 0	7.5.C. 99 120 and/or 121.	
_	int(s) ice of References Cited (PTO-892)	4) Interview Summary	r (PTO-413) Paper No(s).	
	ice of Draftsperson's Patent Drawing Review (PTO-948)		Patent Application (PTO-152)	
3) 🗌 Info	rmation Disclosure Statement(s) (PTO-1449) Paper No(s),	6) 💢 Other: Detailed	Action	

Art Unit: 1634

DETAILED ACTION

Current status of the Application

1. Claim 1 has been amended. Currently claims 1-20 are pending in this application. Claims 8-20 are withdrawn from further consideration. Therefore, claims 1-7 are under consideration.

Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 3. Claims 1-7 are rejected under 35 U.S.C. 102 (b) as being anticipated by Pinkel et al. (U.S. Patent 5,856,097) (January 5, 1999).

This rejection is based on the fact that "comprising" language of the claims allows any other step(s) or material(s) to be added in the claimed invention.

Pinkel et al. teaches a set of chromosomal probes comprising a 5p chromosomal probe and a probe selected from 17q21 locus specific probe as well as 8q24 locus specific probe and chromosome 17 enumeration probe (Column 48, Table 4).

Art Unit: 1634

Pinkel et al. teaches the set of chromosomal probes, wherein different detection moieties are coupled to the two probes comprising fluorescent labels (Column 51, line 8 to column 52, line 42 and Figures 2, 5, and 6).

Pinkel et al inherently teaches the set of chromosomal probes comprising a 5p probe, a 8q24 locus specific probe and 7p probe and 17q21 locus specific probe (Column 48, Table 4 and Figure 17).

Pinkel et al inherently teaches the set of chromosomal probes comprising a 5p probe, a 8q24 locus specific probe and 20q chromosome arm probe and 7p locus specific probe (Column 48, Table 4 and Figure 17).

This inherency is based on the fact that Pinkel et al teaches broadly all chromosomal probes (Figure 17) as Pinkel states, "When CGH is applied, for example, in the fields of tumor cytogenetics and prenatal diagnosis, it provides methods to determine whether there are abnormal copy numbers of nucleic acid sequences *anywhere* in the genome of a subject tumor cell or fetal cell or the genomes from representative cells from a tumor cell population or from a number of fetal cells, without having to prepare condensed chromosome spreads from those cells (Column 3, lines 32-39)". Although the specific numbers such as 5p15 and 7p12 are not mentioned by Pinkel et al., these probes are inherently present in the combination of probes of Pinkel et al because "it provides methods to determine whether there are abnormal copy numbers of nucleic acid sequences *anywhere* in the genome of a subject tumor cell".

Application/Control Number: 10/081,393 Page 4

Art Unit: 1634

Moreover, MPEP 2123 also states "A reference may be relied upon for all that it would have reasonably suggested to one having ordinary skill the art, including nonpreferred embodiments. Merck & Co. v. Biocraft Laboratories, 10 USPQ2d 1843 (Fed. Cir. 1989)."

Although Pinkel et al. reference uses certain combination of probes to detect certain loci on the chromosome, Pinkel et al teaches that such probes can detect abnormal copy numbers of nucleic acid sequences *anywhere* in the genome of a subject tumor cell. Moreover, MPEP 2111 states, "Claims must be given their broadest reasonable interpretation. During patent examination, the pending claims must be "given the broadest reasonable interpretation consistent with the specification". Applicant always has the opportunity to amend the claims during prosecution and broad interpretation by the examiner reduces the possibility that the claim, once issued, will be interpreted more broadly than it is justified. *In re Prater*, 415 F.2d 1393, 1404-05, 162 USPQ 541, 550-51 (CCPA 1969)". In this case, in presence of "comprising" language of the claims, any combination of probes as taught by Pinkel et al., can be used for detecting abnormal copy numbers of nucleic acid sequences *anywhere* in the genome of a subject tumor cell.

Response to Amendment

4. In response to amendment, previous 102(b) and 103(a) rejections are hereby withdrawn.

Response to Arguments

Application/Control Number: 10/081,393 Page 5

Art Unit: 1634

.5. Applicant's arguments with respect to all pending claims have been considered but are moot in view of the new ground(s) of rejection.

Conclusion

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Arun Chakrabarti, Ph.D. whose telephone number is (703) 306-5818.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion, can be reached on (703) 308-1119.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group LIE Chantae Dessau whose telephone number is (703) 605-1237.

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission via the P.T.O. Fax Center located in Crystal Mall 1. The CM1 Fax Center numbers for Technology Center 1600 is (703) 872-9306. Please note that the faxing of such papers must conform with the Notice to Comply published in the Official Gazette, 1096 OG 30 (November 15, 1989).

ARUN K. CHAKRABARTI Arun Chakrabarti PATENT EXAMINER Patent Examiner

Art Unit 1634

November 4, 2003

GARY BENZION, PH.D SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600

Notice of References Cited

Application/Control No. Applicant(s)/Patent Under Reexam 10/081,393 Morrison Art Unit Examiner Arun Chakrabarti 1634 Page 1 of 1

U.S. PATENT DOCUMENTS

		Document Number Date Number-Kind Code MM-YYYY Name		Classification ²		
*	A	5,856,097	1/1999	Pinkel	435	6
	В					
	С					
	D					
	E				_	
	F	,			t	
	G					
	н					
	1					
	J					
	K					
	L					
	М					

FOREIGN PATENT DOCUMENTS

	Document Number Country Code-Number-Kind Code	Date MM-YYYY¹	Country	Name	Classification ²
N					
0					
Р					
a					
R					
s					
Т					

NON-PATENT DOCUMENTS

	Include, as applicable: Author, Title, Date, Publisher, Edition or Volume, Pertinent Pages
υ	
v	
w	
x	

^{*} A copy of this reference is not being furnished with this Office action. See MPEP § 707.05(a). 1 Dates in MM-YYYY format are publication dates.

 $^{^{2}}$ Classifications may be U.S. or foreign,

